Matches in SemOpenAlex for { <https://semopenalex.org/work/W4232181833> ?p ?o ?g. }
- W4232181833 endingPage "321" @default.
- W4232181833 startingPage "311" @default.
- W4232181833 abstract "Retinal and choroidal vascular diseases constitute the most common causes of moderate and severe vision loss in developed countries. They can be divided into retinal vascular diseases, in which there is leakage and/or neovascularization (NV) from retinal vessels, and subretinal NV, in which new vessels grow into the normally avascular outer retina and subretinal space. The first category of diseases includes diabetic retinopathy, retinal vein occlusions, and retinopathy of prematurity, and the second category includes neovascular age-related macular degeneration (AMD), ocular histoplasmosis, pathologic myopia, and other related diseases. Retinal hypoxia is a key feature of the first category of diseases resulting in elevated levels of hypoxia-inducible factor-1 (HIF-1) which stimulates expression of vascular endothelial growth factor (VEGF), platelet-derived growth factor-B (PDGF-B), placental growth factor, stromal-derived growth factor-1 and their receptors, as well as other hypoxia-regulated gene products such as angiopoietin-2. Although hypoxia has not been demonstrated as part of the second category of diseases, HIF-1 is elevated and thus the same group of hypoxia-regulated gene products plays a role. Clinical trials have shown that VEGF antagonists provide major benefits for patients with subretinal NV due to AMD and even greater benefits are seen by combining antagonists of VEGF and PDGF-B. It is likely that addition of antagonists of other agents listed above will be tested in the future. Other appealing strategies are to directly target HIF-1 or to use gene transfer to express endogenous or engineered anti-angiogenic proteins. While substantial progress has been made, the future looks even brighter for patients with retinal and choroidal vascular diseases." @default.
- W4232181833 created "2022-05-12" @default.
- W4232181833 creator A5085965174 @default.
- W4232181833 date "2013-01-18" @default.
- W4232181833 modified "2023-10-10" @default.
- W4232181833 title "Ocular neovascularization" @default.
- W4232181833 cites W1481978003 @default.
- W4232181833 cites W1486264823 @default.
- W4232181833 cites W1537192388 @default.
- W4232181833 cites W1547863599 @default.
- W4232181833 cites W1600542667 @default.
- W4232181833 cites W1875554126 @default.
- W4232181833 cites W1967004211 @default.
- W4232181833 cites W1970494874 @default.
- W4232181833 cites W1970614272 @default.
- W4232181833 cites W1972325477 @default.
- W4232181833 cites W1975107877 @default.
- W4232181833 cites W1976384923 @default.
- W4232181833 cites W1977532338 @default.
- W4232181833 cites W1977753425 @default.
- W4232181833 cites W1984038456 @default.
- W4232181833 cites W1994014733 @default.
- W4232181833 cites W1996430165 @default.
- W4232181833 cites W1996870435 @default.
- W4232181833 cites W2000383031 @default.
- W4232181833 cites W2000811703 @default.
- W4232181833 cites W2002979159 @default.
- W4232181833 cites W2003797682 @default.
- W4232181833 cites W2004117352 @default.
- W4232181833 cites W2005215351 @default.
- W4232181833 cites W2007057348 @default.
- W4232181833 cites W2015344488 @default.
- W4232181833 cites W2015394351 @default.
- W4232181833 cites W2024524941 @default.
- W4232181833 cites W2026919841 @default.
- W4232181833 cites W2033705784 @default.
- W4232181833 cites W2034458870 @default.
- W4232181833 cites W2037348124 @default.
- W4232181833 cites W2042523510 @default.
- W4232181833 cites W2049350428 @default.
- W4232181833 cites W2049624292 @default.
- W4232181833 cites W2050801925 @default.
- W4232181833 cites W2050837805 @default.
- W4232181833 cites W2053060309 @default.
- W4232181833 cites W2053296388 @default.
- W4232181833 cites W2059108446 @default.
- W4232181833 cites W2063402166 @default.
- W4232181833 cites W2064369986 @default.
- W4232181833 cites W2064489090 @default.
- W4232181833 cites W2064894017 @default.
- W4232181833 cites W2068403296 @default.
- W4232181833 cites W2070613014 @default.
- W4232181833 cites W2072839085 @default.
- W4232181833 cites W2073327993 @default.
- W4232181833 cites W2073415458 @default.
- W4232181833 cites W2075086348 @default.
- W4232181833 cites W2077954885 @default.
- W4232181833 cites W2080196370 @default.
- W4232181833 cites W2081417168 @default.
- W4232181833 cites W2082666818 @default.
- W4232181833 cites W2085609942 @default.
- W4232181833 cites W2085712747 @default.
- W4232181833 cites W2086268489 @default.
- W4232181833 cites W2088255586 @default.
- W4232181833 cites W2088726343 @default.
- W4232181833 cites W2089334167 @default.
- W4232181833 cites W2091407629 @default.
- W4232181833 cites W2091415724 @default.
- W4232181833 cites W2091989599 @default.
- W4232181833 cites W2098155102 @default.
- W4232181833 cites W2114098415 @default.
- W4232181833 cites W2114147340 @default.
- W4232181833 cites W2124415048 @default.
- W4232181833 cites W2124974853 @default.
- W4232181833 cites W2128154767 @default.
- W4232181833 cites W2128210855 @default.
- W4232181833 cites W2130395392 @default.
- W4232181833 cites W2131798870 @default.
- W4232181833 cites W2135664375 @default.
- W4232181833 cites W2137061409 @default.
- W4232181833 cites W2142886240 @default.
- W4232181833 cites W2143343444 @default.
- W4232181833 cites W2147358575 @default.
- W4232181833 cites W2147656680 @default.
- W4232181833 cites W2148596615 @default.
- W4232181833 cites W2152215024 @default.
- W4232181833 cites W2157930949 @default.
- W4232181833 cites W2161877652 @default.
- W4232181833 cites W2163252729 @default.
- W4232181833 cites W2163751790 @default.
- W4232181833 cites W2165849226 @default.
- W4232181833 cites W2166083606 @default.
- W4232181833 cites W2168305884 @default.
- W4232181833 cites W2169906117 @default.
- W4232181833 cites W2214510433 @default.
- W4232181833 cites W2324588265 @default.
- W4232181833 cites W2331634724 @default.
- W4232181833 cites W2397720197 @default.